Physician profile
Robert Gerard Cheron
NPI 1558382390
$3,186.41
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,047 · 2020: $139.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $723.54 | 2019-2020 | |
| Novo Nordisk INC | $573.47 | 2019 | |
| Lilly USA, LLC | $396.23 | 2019 | |
| Alexion Pharmaceuticals, INC. | $286.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $253.46 | 2019 | |
| Biotronik INC. | $195.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.17 | 2019 | |
| Mannkind Corporation | $155.54 | 2019 | |
| Amarin Pharma, INC. | $125.57 | 2019 | |
| Radius Health, INC. | $82.46 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $71.70 | 2019 | |
| Abbvie INC. | $51.17 | 2019 | |
| Pfizer INC. | $24.50 | 2019 | |
| Merck Sharp & Dohme LLC | $15.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.99 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $13.35 | 2019 | |
| Eisai INC. | $13.05 | 2019 | |
| Therapeuticsmd, INC. | $11.66 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $8.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cheron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.